The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Assessing the outcomes of patients with myeloma with deletion 1p following autoSCT
Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the findings of a single-arm retrospective analysis of the outcomes following autologous stem cell transplant (autoSCT) in patients with multiple myeloma (MM) and deletion of part of the short arm of chromosome 1 (del1p). Prof. Qazilbash highlights the differences in progression-free survival (PFS) between these patients and the general myeloma population with comparable induction treatment and transplant regimens and explains that future studies will explore this population in greater detail. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Multiple myeloma, there are between 15 to 30 percent patients, depending on which data you look at, considered to have high-risk chromosomal abnormalities. Some of them are very well known. Others, like deletion 1p, is still being evaluated. So we looked at our data set and we found 55 patients who had deletion 1p. And deletion 1p basically means that a small part of the short arm of chromosome 1 is missing, which has a tumor suppressor gene...
Multiple myeloma, there are between 15 to 30 percent patients, depending on which data you look at, considered to have high-risk chromosomal abnormalities. Some of them are very well known. Others, like deletion 1p, is still being evaluated. So we looked at our data set and we found 55 patients who had deletion 1p. And deletion 1p basically means that a small part of the short arm of chromosome 1 is missing, which has a tumor suppressor gene. In our case, we look at CDKN2C. It’s a tumor suppressor gene that basically inhibits cell cycle progression. So when that is missing, the tumor can progress. So we looked at 55 patients that we transplanted at our center with deletion 1p and their outcomes. And we saw that their median progression-free survival was about 30 months, which is less than what we generally see in our myeloma patients, but some of these were treated over a number of years when the outcomes were not that good. In terms of their induction treatment and transplant regimens, they were comparable to our other patients, but we noticed that their progression-free survival was 30 months. So we looked at an internal control. We identified 110 patients, a two-to-one ratio to deletion 1p patients, and compared their outcomes to those. So briefly, if we look at the median progression-free survival, that was not significantly different. Although patients with deletion 1p had somewhat shorter survival, but because of perhaps a smaller number, it did not reach statistical significance. So this is a good finding. There are other groups that are looking at deletion 1p. We are going to be looking at it in greater detail. What if there is one missing copy versus two missing copies and if that has greater significance. And we’re going to add some more patients because this analysis went up to 2021. And since then, we would, of course, have several more patients that we can include in our subsequent analysis. So that basically is what we are showing in terms of patients with deletion 1p and multiple myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
BioLineRx: Research Funding; NexImmune: Research Funding; Janssen Pharmaceuticals: Research Funding; Angiocrine Bioscience: Research Funding; Amgen: Research Funding.
